Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development

被引:94
作者
Blomme, Eric A. G. [1 ]
Yang, Yi [1 ]
Waring, Jeffrey F. [1 ]
机构
[1] Abbott Labs, Dept Cellular Mol & Exploratory Toxicol, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
Toxicogenomics; Hepatotoxicity; Mechanistic; Biomarker; Enzyme induction; GENE-EXPRESSION ANALYSIS; INDUCED LIVER-INJURY; IN-VITRO; INDUCED PHOSPHOLIPIDOSIS; HUMAN HEPATOCYTES; RAT-LIVER; OXIDATIVE STRESS; HEPG2; CELLS; CARBOXYLASE INHIBITORS; IDIOSYNCRATIC TOXICITY;
D O I
10.1016/j.toxlet.2008.09.017
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Hepatotoxicity is a common cause of failure in drug discovery and development and is also frequently the source of adverse drug reactions. Therefore, a better prediction, characterization and understanding of drug-induced hepatotoxicity could result in safer drugs and a more efficient drug discovery and development process. Among the 'omics technologies, toxicogenomics (or the use of gene expression profiling in toxicology) represents an attractive approach to predict toxicity and to gain a mechanistic understanding of toxic changes. In this review, we illustrate, using selected examples, how toxicogenomics can be applied to investigate drug-induced hepatotoxicity in animal models and in vitro systems. In general, this technology can not only improve the discipline of toxicology and risk assessment but also represent an extremely effective, hypothesis-generating alternative to rapidly understand mechanisms of hepatotoxicity. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 84 条
  • [1] The relationship among microsomal enzyme induction, liver weight, and histological change in cynomolgus monkey toxicology studies
    Amacher, DE
    Schomaker, SJ
    Boldt, SE
    Mirsky, M
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2006, 44 (04) : 528 - 537
  • [2] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells
    Atienzar, Franck
    Gerets, Helga
    Dufrane, Simon
    Tilmant, Karen
    Cornet, Miranda
    Dhalluin, Stephane
    Ruty, Bernard
    Rose, Geoffrey
    Canning, Michael
    [J]. TOXICOLOGICAL SCIENCES, 2007, 96 (01) : 101 - 114
  • [3] Hepatotoxicity in drug development: Detection, significance and solutions
    Ballet, F
    [J]. JOURNAL OF HEPATOLOGY, 1997, 26 : 26 - 36
  • [4] The safety profile of the fluoroquinolones
    Bertino, J
    Fish, D
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (07) : 798 - 817
  • [5] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [6] BLOMME EA, 2008, PRECLINICAL DEV HDB, P867
  • [7] BLOMME EA, 2007, VET PATHOL, V44, P781
  • [8] Evaluation of the effects of serial phlebotomy on the transcriptome of major tissues and on the response to toxicants in rats
    Blomme, Eric A. G.
    Ciurlionis, Rita
    Marsh, Kennan C.
    Waring, Jeffrey F.
    Yang, Yi
    [J]. TOXICOLOGY LETTERS, 2008, 176 (02) : 138 - 148
  • [9] An in vitro study on 5-HT6 receptor antagonist induced hepatotoxicity based on biochemical assays and toxicogenomics
    Boess, F.
    Durr, E.
    Schaub, N.
    Haiker, A.
    Albertini, S.
    Suter, L.
    [J]. TOXICOLOGY IN VITRO, 2007, 21 (07) : 1276 - 1286
  • [10] Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies
    Boone, L
    Meyer, D
    Cusick, P
    Ennulat, D
    Bolliger, AP
    Everds, N
    Meador, V
    Elliott, G
    Honor, D
    Bounous, D
    Jordan, H
    [J]. VETERINARY CLINICAL PATHOLOGY, 2005, 34 (03) : 182 - 188